Citations

Showing 10 of 108094 citations.

The Heart-Brain Team—Towards Optimal Team-Based Coordinated Care
Graff‐Radford, Jonathan , Holmes, David R. , Alkhouli, Mohamad

Mayo Clinic

JAMA Cardiology | January 17, 2018 | Volume: 3 | Issue: 3 | Pages: 187

10.1001/jamacardio.2017.5072 | PMID 29344618 Get It

Histological features and outcome of inverted type‐A melanocytic nevi
Dadras, Soheil S. , Zembowicz, Artur, Flotte, Thomas J. , Mihm, Martín C. , Lu, Jun

Mayo Clinic

Journal of Cutaneous Pathology | January 17, 2018 | Volume: 45 | Issue: 4 | Pages: 254-262

10.1111/cup.13106 | PMID 29341232 Get It

The presence of enlarged epithelioid/spindled nests located deep in the reticular dermis of a biphasic melanocytic neoplasm can mimic melanoma arising in a pre‐existing nevus, causing over‐interpretation of malignancy. We aimed to define the clinicopathologic significance of epithelioid/spindled nests in melanocytic nevi. Retrospectively using clinical and histologic information, we characterized 121 patients with a single lesion showing epithelioid/spindled melanocytes in the reticular dermis or subcutaneous fat, surrounded by melanophages, sometimes blending in with the adnexa. The majority of nevi occurred in women in the ages of 10 to 39 years, where the most frequent presentation was a changing mole. While 78% of the lesions displayed an anatomic (Clark’s) level of IV‐V, there was no ulceration, significant regression or inflammation. Up to 2 mitoses were found in only 12% of the cases, not correlating with the severity of cytological atypia. No recurrence or metastasis occurred during 45.5 months (mean) of clinical follow up in 26 patients. Notwithstanding the deep dermal extension, these findings suggest a benign histopathology and clinical outcome. Having compared the overlapping histopathology and clinical features between deep penetrating/clonal nevus and combined nevus, we posit that “inverted type‐A nevus” might be considered a variant of the two.
A Natural Human Monoclonal Antibody Protects from Axonal Injury in Different CNS Degenerative Disease Models
Kunbaz, Ahmad , Warrington, Arthur E. , Perwein, Maria Katharina Elisabeth , Fereidan-Esfahani, Mahboobeh , Rodriguez, Moses , Rodriguez, Moses

Mayo Clinic

Future Neurology | January 17, 2018 | Volume: 13 | Issue: 1 | Pages: 23-29

10.2217/fnl-2017-0027 Get It

Current and Emerging Multianalyte Assays with Algorithmic Analyses—Are Laboratories Ready for Clinical Adoption?
Colón-Franco, Jessica M , Bossuyt, Patrick M M, Algeciras-Schimnich, Alicia , Engstrom-Melnyk, Julia, Fleisher, Martin, Kattan, Michael W. , Bossuyt, Patrick M M, Bird, Chris , Lambert-Messerlian, Geralyn M. , Kattan, Michael W

Mayo Clinic

Clinical Chemistry | January 17, 2018 | Volume: 64 | Issue: 6 | Pages: 885-891

10.1373/clinchem.2017.275677 | PMID 29343536 Get It

Debates in Pain Management Testing
Melanson, Stacy E.F. , Clarke, William , Fragoza, Keith , Gilligan, Christopher , Holdren, Rebecca, Jannetto, Paul J. , Magnani, B, Moore, Christine

Mayo Clinic

Clinical Chemistry | January 17, 2018 | Volume: 64 | Issue: 5 | Pages: 769-776

10.1373/clinchem.2017.275693 | PMID 29343535 Get It

Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers o
Wu, Alan H.B. , Christenson, Robert H. , Greene, Dina N. , Jaffe, Allan S. , Kavsak, Peter A. , Ordóñez‐Llanos, Jordi , Apple, Fred S. , Jaffe, Allan S. , Greene, Dina

Mayo Clinic

Clinical Chemistry | January 17, 2018 | Volume: 64 | Issue: 4 | Pages: 645-655

10.1373/clinchem.2017.277186 | PMID 29343532 Get It

Abstract This document is an essential companion to the third iteration of the National Academy of Clinical Biochemistry [NACB,8 now the American Association for Clinical Chemistry (AACC) Academy] Laboratory Medicine Practice Guidelines (LMPG) on cardiac markers. The expert consensus recommendations were drafted in collaboration with the International Federation of Clinical Chemistry and Laboratory Medicine Task Force on Clinical Applications of Bio-Markers (IFCC TF-CB). We determined that there is sufficient clinical guidance on the use of cardiac troponin (cTn) testing from clinical practice groups. Thus, in this expert consensus document, we focused on clinical laboratory practice recommendations for high-sensitivity (hs)-cTn assays. This document utilized the expert opinion class of evidence to focus on the following 10 topics: (a) quality control (QC) utilization, (b) validation of the lower reportable analytical limits, (c) units to be used in reporting measurable concentrations for patients and QC materials, (d) 99th percentile sex-specific upper reference limits to define the reference interval; (e) criteria required to define hs-cTn assays, (f) communication with clinicians and the laboratory's role in educating clinicians regarding the influence of preanalytic and analytic problems that can confound assay results, (g) studies on hs-cTn assays and how authors need to document preanalytical and analytical variables, (h) harmonizing and standardizing assay results and the role of commutable materials, (i) time to reporting of results from sample receipt and sample collection, and (j) changes in hs-cTn concentrations over time and the role of both analytical and biological variabilities in interpreting results of serial blood collections.
What are the outcomes of declining a public health service increased risk liver donor for patients on the liver transplant waiting list?
Croome, Kristopher P. , Lee, David D. , Pungpapong, Surakit , Taner, C. Burcin , Croome, Kris P , Lee, David D , Pungpapong, Surakit , Keaveny, Andrew P.

Mayo Clinic

Liver Transplantation | January 17, 2018 | Volume: 24 | Issue: 4 | Pages: 497-504

10.1002/lt.25009 | PMID 29341398 Get It

The tragedy of the national opioid epidemic has resulted in a significant increase in the number of opioid‐related deaths and accordingly an increase in the number of potential donors designated Public Health Service (PHS) increased risk. Previous studies have demonstrated reluctance to use these PHS organs, and as a result, higher discard rates for these organs have been observed. All patients listed for liver transplantation in the United States from January 2005 to December 2016 were investigated. Patients on the waiting list were divided into 2 groups: those in which a PHS liver was used for transplantation (accepted PHS group) and those in which a PHS liver was declined and transplanted into a recipient lower on the match run (declined PHS group). Intention‐to‐treat patient survival from the time of PHS offer was significantly higher in the accepted PHS compared with the declined PHS group (P < 0.001). On Cox multivariate regression, declining a PHS donor liver was associated with a hazard ratio of 2.36 (95% confidence interval, 2.23‐2.49; P < 0.001). For patients in which a PHS organ offer was declined, 11.6% died or were delisted for being too sick within the subsequent year. Donor liver allografts implanted in the accepted PHS group were of a lower donor risk index (1.28 versus 1.44) compared with the non‐PHS organs that patients in the declined PHS group ultimately received if they underwent transplantation. In conclusion, there is a significantly higher survival for patients in which a PHS liver is accepted and used compared with those patients in which a PHS organ is declined. These data will help inform decisions about whether or not to accept a PHS donor liver for both patients and transplant professionals. Liver Transplantation 24 497–504 2018 AASLD.
Statin use and the risk of cardiovascular implantable electronic device infection: A cohort study in a veteran population
Alzahrani, Talal , Liappis, Angelike P., Karasik, Pamela , Baddour, Larry M.

Mayo Clinic

Pacing and Clinical Electrophysiology | January 17, 2018 | Volume: 41 | Issue: 3 | Pages: 284-289

10.1111/pace.13285 | PMID 29341172 Get It

AbstractBackgroundThe rate of cardiovascular implantable electronic device infection (CIEDI) has increased, despite the use of perioperative antibiotics at the time of device placement or revision. This is due, in part, to the presence of multiple comorbid conditions in an elderly population, in general, who require CIED. Statins may have an antibacterial effect, although there is currently no evidence that the likelihood of CIEDI has been impacted by statin use.MethodsA retrospective cohort study was performed to assess whether statins are associated with a reduced risk of CIEDI. The VA Informatics and Computing Infrastructure (VINCI) database, which includes all veterans who underwent CIED placement between 2008 and 2015, was used. A logistic regression model was constructed to estimate the adjusted risk of CIEDI among patients who were receiving statins after adjusting for confounding factors.ResultsOverall, 18,970 CIED procedures were included, and 98% of them were performed in men with a mean age of 71 ± 11 years. The rate of diabetes mellitus, heart failure, advanced chronic kidney diseases, CIEDI, positive methicillin‐resistant Staphylococcus aureus nasal colonization, and statin use were 23%, 15.7%, 3.3%, 1.14%, 12.6%, and 56%, respectively. The logistic regression analysis showed that statins were significantly associated with a reduced risk of CIEDI; after controlling for other effects, the reduction was 66% (odds ratio 0.34 [0.2–0.59], P‐value < 0.001). The effect of statins was confirmed by propensity score analysis.ConclusionsOur study showed that among patients receiving statins who had undergone CIED placement, there was a 66% reduction in subsequent CIEDI.
Core Content for Wilderness Medicine Training: Development of a Wilderness Medicine Track Within an Emergency Medicine Residency
Schrading, Walter A. , Battaglioli, Nicole , Drew, Jonathan , McClure, Sarah Frances

Mayo Clinic

Wilderness & Environmental Medicine | January 17, 2018 | Volume: 29 | Issue: 1 | Pages: 78-84

10.1016/j.wem.2017.10.003 | PMID 29373220 Get It

Wilderness medicine training has become increasingly popular among medical professionals with numerous educational opportunities nationwide. Curricula for fellowship programs and for medical student education have previously been developed and published, but a specific curriculum for wilderness medicine education during emergency medicine (EM) residency has not. The objective of this study is to create a longitudinal wilderness medicine curriculum that can be incorporated into an EM residency program. Interest-specific tracks are becoming increasingly common in EM training. We chose this model to develop our curriculum specific to wilderness medicine. Outlined in the article is a 3-year longitudinal course of study that includes a core didactic curriculum and a plan for graduated level of responsibility. The core content is specifically related to the required EM core content for residency training with additions specific to wilderness medicine for the residents who pursue the track. The wilderness medicine curriculum would give residencies a framework that can be used to foster learning for residents interested in wilderness medicine. It would enhance the coverage of wilderness and environmental core content education for all EM residents in the program. It would provide wilderness-specific education and experience for interested residents, allowing them to align their residency program requirements through a focused area of study and enhancing their curriculum vitae at graduation. Finally, given the popularity of wilderness medicine, the presence of a wilderness medicine track may improve recruitment for the residency program.
Personality Changes During the Transition from Cognitive Health to Mild Cognitive Impairment
Caselli, Richard J. , Langlais, Blake, Dueck, Amylou C. , Henslin, Bruce R. , Johnson, Travis A. , Woodruff, Bryan K. , Hoffman‐Snyder, Charlene , Langlais, Blake T., Locke, Dona E.C. , Dueck, A. C.

Mayo Clinic

Journal of the American Geriatrics Society | January 17, 2018 | Volume: 66 | Issue: 4 | Pages: 671-678

10.1111/jgs.15182 | PMID 29341070 Get It

Background/Objectives Behavioral problems in individuals with Alzheimer's disease ( AD ) impose major management challenges. Current prevention strategies are anchored to cognitive outcomes, but behavioral outcomes may provide another, clinically relevant opportunity for preemptive therapy. We sought to determine whether personality changes that predispose to behavioral disorders arise during the transition from preclinical AD to mild cognitive impairment ( MCI ). Design Longitudinal observational cohort study. Setting Academic medical center. Participants Members of an apolipoprotein E ( APOE ) ɛ4 genetically enriched cohort of Maricopa County residents who were neuropsychiatrically healthy at entry (N = 277). Over a mean interval of 7 years, 25 who developed MCI and had the Neuroticism, Extraversion, and Openness Personality Inventory—Revised ( NEO ‐ PI ‐R) before and during the MCI transition epoch were compared with 252 nontransitioners also with serial NEO ‐ PI ‐R administrations. Intervention Longitudinal administration of the NEO ‐ PI ‐R and neuropsychological test battery. Measurements Change in NEO ‐ PI ‐R factor scores (neuroticism, extraversion, openness, agreeableness, conscientiousness) from entry to the epoch of MCI diagnosis or an equivalent follow‐up duration in nontransitioners. Results NEO ‐ PI ‐R neuroticism T‐scores increased significantly more in MCI transitioners than in nontransitioners (mean 2.9, 95% confidence interval ( CI ) = 0.9–4.9 vs 0, 95% CI = −0.7–0.7, P = .02), and openness decreased more in MCI transitioners than in nontransitioners (−4.8, 95% CI = −7.3 to −2.4 vs −1.0, 95% CI = −1.6 to −0.4, P < .001). Concurrent subclinical but statistically significant changes in behavioral scores worsened more in MCI transitioners than nontransitioners for measures of depression, somatization, irritability, anxiety, and aggressive attitude. Conclusion Personality and subclinical behavioral changes begin during the transition from preclinical AD to incident MCI and qualitatively resemble the clinically manifest behavioral disorders that subsequently arise in individuals with frank dementia.